z-VAD-FMK triggers macrophage necroptosis in mycobacterial infection
A new study finds that the common pan-caspase inhibitor z-VAD-FMK can drive necroptosis in macrophages infected with Mycobacterium tuberculosis and related bacteria through an off-target mechanism. The findings could reshape how researchers think about cell death in tuberculosis and point to new host-directed treatment strategies.
Why it matters: - Macrophage death during Mycobacterium tuberculosis infection can worsen tissue damage and help the bacterium spread. - The study identifies z-VAD-FMK as a trigger of necroptosis in infected macrophages, which could affect how researchers interpret cell-death experiments in tuberculosis. - The findings also point to necroptosis as a disease driver in some TB settings and a possible target for host-directed therapy.
What happened: - Researchers led by Li Zhang at Southern University of Science and Technology found that z-VAD-FMK triggered robust necroptosis in macrophages infected with Mycobacterium tuberculosis, Mycobacterium kansasii, or Rhodococcus equi. - The effect came from a non-canonical off-target mechanism, not from caspase-8 inhibition. - The work was published under DOI 10.1002/mlf2.70101.
The details: - Genetic and pharmacological tests showed the cell death depended on the RIPK1-RIPK3-MLKL axis, TLR2-TNF-α signaling, and type I interferon signaling. - Mouse caspase-8 knockdown and human caspase-8 knockout in macrophages did not eliminate z-VAD-FMK-triggered necroptosis during mycobacterial infection. - Other selective caspase inhibitors did not reproduce the same effect. - RIPK3 became functionally activated without detectable phosphorylation at the canonical T231/S232 sites, suggesting an alternative activation route. - The same off-target necroptosis appeared in macrophages infected with Mycobacterium kansasii and Rhodococcus equi, two bacteria related to M. tuberculosis. - In wild-type C57BL/6 mice, MLKL deletion had little effect on tuberculosis outcome. - In Sp140-/- mice with elevated type I interferon responses and necrotic granulomas, MLKL deficiency reduced weight loss, lowered bacterial burden, and lessened lung pathology after high-dose aerosol infection. - The study was supported by grants from the National Natural Science Foundation of China, the Guangdong Basic and Applied Basic Research Foundation, the Shenzhen Science and Technology Program, the National Institutes of Health, and the Milstein Program in Chemical Biology and Translational Medicine.
Between the lines: - z-VAD-FMK is widely used as a pan-caspase inhibitor, so this off-target activity could complicate past and future cell-death studies. - The results suggest that necroptosis may matter more in inflammatory, type I interferon-high TB settings than in standard infection models. - The study also raises the possibility that the real molecular target of z-VAD-FMK remains unidentified.
What's next: - The authors say identifying the true target of z-VAD-FMK could clarify how necrotic granulomas form during tuberculosis. - The findings may help guide future host-directed therapies aimed at limiting damaging macrophage death in TB. - The DOI link to the paper is the full study.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Science Times Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.